Kontafarma China Holdings Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Feifei Wang
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | less than a year |
Recent management updates
Recent updates
Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?
Dec 20
Kontafarma China Holdings Limited's (HKG:1312) Price Is Right But Growth Is Lacking After Shares Rocket 44%
Oct 09Is Kontafarma China Holdings (HKG:1312) Weighed On By Its Debt Load?
Sep 04Here's Why Kontafarma China Holdings Limited's (HKG:1312) CEO Compensation Is The Least Of Shareholders Concerns
May 31There's No Escaping Kontafarma China Holdings Limited's (HKG:1312) Muted Revenues Despite A 61% Share Price Rise
May 24Health Check: How Prudently Does Kontafarma China Holdings (HKG:1312) Use Debt?
Dec 28Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?
Sep 01Is Kontafarma China Holdings (HKG:1312) Using Debt Sensibly?
Dec 29Health Check: How Prudently Does Tongfang Kontafarma Holdings (HKG:1312) Use Debt?
Sep 15Tongfang Kontafarma Holdings (HKG:1312) Has Debt But No Earnings; Should You Worry?
Apr 20Is Tongfang Kontafarma Holdings (HKG:1312) A Risky Investment?
Nov 04Tongfang Kontafarma Holdings' (HKG:1312) Shareholders Are Down 90% On Their Shares
Feb 18These 4 Measures Indicate That Tongfang Kontafarma Holdings (HKG:1312) Is Using Debt Extensively
Dec 07CEO
Feifei Wang
less than a year
Tenure
Mr. Feifei Wang is Executive Chairman & President of Kontafarma China Holdings Limited from June 7, 2024.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & President | less than a year | no data | no data | |
| Financial Controller & Executive Director | less than a year | no data | no data | |
| Chief Operating Officer | 4.3yrs | no data | no data | |
| VP & Executive Director | less than a year | no data | no data | |
| Executive Director | less than a year | no data | no data | |
| Company Secretary | less than a year | no data | no data |
0.5yrs
Average Tenure
Experienced Management: 1312's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & President | less than a year | no data | no data | |
| Financial Controller & Executive Director | less than a year | no data | no data | |
| VP & Executive Director | less than a year | no data | no data | |
| Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Non-Executive Director | 10.8yrs | HK$1.67m | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data |
0.5yrs
Average Tenure
57.5yo
Average Age
Experienced Board: 1312's board of directors are not considered experienced ( 0.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 10:17 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kontafarma China Holdings Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|